How useful is the 'cocktail approach' for evaluating human hepatic drug metabolizing capacity using cytochrome P450 phenotyping probes in vivo?

Journal of Clinical Pharmacy and Therapeutics

Volumn 28, Issue 3, 2003, Pages 157-165

  Tanaka, Einosuke ^a   Kurata, N ^b   Yasuhara, H ^b  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cytochrome P450; Drug metabolism; Polymorphism; Probes

Indexed keywords

CAFFEINE; CHLORZOXAZONE; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4;

ANALYTIC METHOD; DRUG METABOLISM; DRUG OXIDATION; ENZYME ACTIVITY; ENZYME ANALYSIS; FEMALE; GENETIC POLYMORPHISM; HUMAN; LIVER METABOLISM; MALE; PHENOTYPE; REVIEW;

ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP2E1; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; LIVER; MALE; MIXED FUNCTION OXYGENASES; MOLECULAR PROBES; PHARMACEUTICAL PREPARATIONS; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC;

EID: 0037803539     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.2003.00486.x     Document Type: Review

References (60)

1. Kivisto KT, Kroemer HK (1997) Use of probe drugs as predictors of drug metabolism in humans. Journal of Clinical Pharmacology, 37 (1 Suppl.), 40S-48S.
2. Zaigler M, Tantcheva-Poor I, Fuhr U (2000) Problems and perspectives of phenotyping for drug-metabolizing enzymes in man. International Journal of Clinical Pharmacology and Therapeutics, 38, 1-9.
3. Streetman DS, Bertino JS Jr, Nafziger AN (2000) Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics, 10, 187-216.
4. Tanaka E, Breimer DD (1997) In vivo function tests of hepatic drug-oxidizing capacity in patients with liver disease. Journal of Clinical Pharmacology and Therapeutics, 22, 237-249.
5. Tanaka E (1998) Clinical importance of non-genetic and genetic cytochrome P450 function tests in liver disease. Journal of Clinical Pharmacology and Therapeutics, 23, 161-170.
6. Frye RF, Matzke GR, Adedoyin A, Porter JA, Branch RA (1997) Validation of the five-drug 'Pittsburgh cocktail' approach for assessment of selective regulation of drug-metabolizing enzymes. Clinical Pharmacology and Therapeutics, 62, 365-376.
7. Adedoyin A, Frye RF, Mauro K, Branch RA (1998) Chloroquine modulation of specific metabolizing enzymes activities: investigation with selective five drug cocktail. British Journal of Clinical Pharmacology, 46, 215-219.
8. Kashuba AD, Nafziger AN, Kearns GL et al. (1998) Effect of fluvoxamine therapy on the activities of CYP1A2, CYP2D6, and CYP3A as determined by phenotyping. Clinical Pharmacology and Therapeutics, 64, 257-268.
9. Brynne N, Bottiger Y, Hallen B, Bertilsson L (1999) Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole. British Journal of Clinical Pharmacology, 47, 145-150.
10. Tenneze L, Verstuyft C, Becquemont L, Poirier JM, Wilkinson GR, Funck-Brentano C (1999) Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination. Clinical Pharmacology and Therapeutics, 66, 582-588.
11. Damkier P, Hansen LL, Brosen K (1999) Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. British Journal of Clinical Pharmacology, 48, 829-838.
12. Damkier P, Brosen K (2000) Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6. Clinical Pharmacology and Therapeutics, 68, 199-209.
13. Streetman DS, Bleakley JF, Kim JS et al. (2000) Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the 'Cooperstown cocktail'. Clinical Pharmacology and Therapeutics, 68, 375-383.
14. Palmer JL, Scott RJ, Gibson A, Dickins M, Pleasance S (2001) An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A). British Journal of Clinical Pharmacology, 52, 555-561.
15. Eap CB, Bondolfi G, Zullino D et al. (2001) Pharmacokinetic drug interaction potential of risperidone with cytochrome p450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test. Therapeutic Drug Monitoring, 23, 228-231.
16. Zhu B, Ou-Yang DS, Chen XP, Huang SL, Tan ZR, He N, Zhou HH (2001) Assessment of cytochrome P450 activity by a five-drug cocktail approach. Clinical Pharmacology and Therapeutics, 70, 455-461.
17. Breimer DD, Schellens JH (1990) A 'cocktail' strategy to assess in vivo oxidative drug metabolism in humans. Trends in Pharmacological Sciences, 11, 223-225.
18. Rostami-Hodjegan A, Nurminen S, Jackson PR, Tucker GT (1996) Caffeine urinary metabolite ratios as markers of enzyme activity: a theoretical assessment. Pharmacogenetics, 6, 121-149.
19. Kalow W, Tang BK (1993) The use of caffeine for enzyme assays: a critical appraisal. Clinical Pharmacology and Therapeutics, 53, 503-514.
20. Sinues B, Saenz MA, Lanuza J, Bernal ML, Fanlo A, Juste JL, Mayayo E (1999) Five caffeine metabolite ratios to measure tobacco-induced CYP1A2 activity and their relationships with urinary mutagenicity and urine flow. Cancer Epidemiology, Biomarkers & Prevention, 8, 159-166.
21. Grant DM, Tang BK, Kalow W (1983) Variability in caffeine metabolism. Clinical Pharmacology and Therapeutics, 33, 591-602.
22. Campbell ME, Grant DM, Inaba T, Kalow W (1987) Biotransformation of caffeine, paraxanthine, theophylline, and theobromine by polycyclic aromatic hydrocarbon-inducible cytochrome(s) P-450 in human liver microsomes. Drug Metabolism and Disposition, 15, 237-249.
23. Rasmussen BB, Brosen K (1996) Determination of urinary metabolites of caffeine for the assessment of cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activity in humans. Therapeutic Drug Monitoring, 18, 254-262.
24. Tanaka E, Ishikawa A, Yamamoto Y et al. (1992) A simple useful method for the determination of hepatic function in patients with liver cirrhosis using caffeine and its three major dimethylmetabolites. International Journal of Clinical Pharmacology, Therapeutics and Toxicology, 30, 336-341.
25. Tanaka E, Ishikawa A, Yamamoto Y, Osada A, Tsuji K, Fukao K, Iwasaki Y (1993) Comparison of hepatic drug-oxidizing activity after simultaneous administration of two probe drugs, caffeine and trimethadione, to human subjects. Pharmacology & Toxicology, 72, 31-33.
26. Miners JO, Birkett DJ (1996) Use of tolbutamide as a substrate probe for human hepatic cytochrome P450 2C9. Methods in Enzymology, 272, 139-145.
27. Chang M, Dahl ML, Tybring G, Gotharson E, Bertilsson L (1995) Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. Pharmacogenetics. 5, 358-363.
28. Lasker JM, Wester MR, Aramsombatdee E, Raucy JL (1998) Characterization of CYP2C19 and CYP2C9 from human liver: respective roles in microsomal tolbutamide, S-mephenytoin, and omeprazole hydroxylations. Archives of Biochemistry and Biophysics, 353, 16-28.
29. Goldstein JA, Faletto MB, Romkes-Sparks M et al. (1994) Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry, 33, 1743-1752.
30. Zhang Y, Blouin RA, McNamara PJ, Steinmetz J, Wedlund PJ (1991) Limitation to the use of the urinary S-/R-mephenytoin ratio in pharmacogenetic studies. British Journal of Clinical Pharmacology, 31, 350-352.
31. Benhamou S, Bouchardy C, Dayer P (1997) Lung cancer risk in relation to mephenytoin hydroxylation activity. Pharmacogenetics, 7, 157-159.
32. Troupin AS, Ojemann LM, Dodrill CB (1976) Mephenytoin: a reappraisal. Epilepsia, 17, 403-414.
33. Sanz EJ, Villen T, Alm C, Bertilsson L (1989) S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. Clinical Pharmacology and Therapeutics, 45, 495-499.
34. Wedlund PJ, Sweetman BJ, Wilkinson GR, Branch RA (1987) Pharmacogenetic association between the formation of 4-hydroxymephenytoin and a new metabolite of S-mephenytoin in man. Drug Metabolism and Disposition, 15, 277-279.
35. Brockmoller J, Rost KL, Gross D, Schenkel A, Roots I (1995) Phenotyping of CYP2C19 with enantiospecific HPLC-quantification of R- and S-mephenytoin and comparison with the intron4/exon5 G-A-splice site mutation. Pharmacogenetics, 5, 80-88.
36. Balian JD, Sukhova N, Harris JW et al. (1995) The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study. Clinical Pharmacology and Therapeutics, 57, 662-669.
37. Capon DA, Bochner F, Kerry N, Mikus G, Danz C, Somogyi AA (1996) The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. Clinical Pharmacology and Therapeutics, 60, 295-307.
38. Schadel M, Wu D, Otton SV, Kalow W, Sellers EM (1995) Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. Journal of Clinical Psychopharmacology, 15, 263-269.
39. Ono S, Hatanaka T, Hotta H, Tsutsui M, Satoh T, Gonzalez FJ (1995) Chlorzoxazone is metabolized by human CYP1A2 as well as by human CYP2E1. Pharmacogenetics, 5, 143-150.
40. Gorski JC, Jones DR, Wrighton SA, Hall SD (1997) Contribution of human CYP3A subfamily members to the 6-hydroxylation of chlorzoxazone. Xenobiotica, 27, 243-256.
41. Mishin VM, Rosman AS, Basu P, Kessova I, Oneta CM, Lieber CS (1998) Chlorzoxazone pharmacokinetics as a marker of hepatic cytochrome P4502E1 in humans. American Journal of Gastroenterology, 93, 2154-2161.
42. Ozdemir V, Kalowa W, Tang BK, Paterson AD, Walker SE, Endrenyi L, Kashuba AD (2000) Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics, 10, 373-388.
43. Wrighton SA, Ring BJ, Watkins PB, VandenBranden M (1989) Identification of a polymorphically expressed member of the human cytochrome P-450III family. Molecular Pharmacology, 36, 97-105.
44. Kolars JC, Awni WM, Merion RM, Watkins PB (1991) First-pass metabolism of cyclosporin by the gut. Lancet, 338, 1488-1490.
45. Thummel KE, Shen DD, Podoll TD et al. (1994) Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. Journal of Pharmacology and Experimental Therapeutics, 271, 557-566.
46. Thummel KE, Shen DD, Podoll TD et al. (1994) Use of midazolam as a human cytochrome P450 3A probe: I. In vitro- in vivo correlations in liver transplant patients. Journal of Pharmacology and Experimental Therapeutics, 271, 549-556.
47. Lown KS, Thummel KE, Benedict PE, Shen DD, Turgeon DK, Berent S, Watkins PB (1995) The erythromycin breath test predicts the clearance of midazolam. Clinical Pharmacology and Therapeutics, 57, 16-24.
48. Kim JS, Kashuba AD, Nafziger AN et al. (1999) Optimal plasma sampling to predict AUC of the CYP3A probe midazolam. Clinical Pharmacology and Therapeutics, 65, 185.
49. May DG, Arns PA, Richards WO et al. (1992) The disposition of dapsone in cirrhosis. Clinical Pharmacology and Therapeutics, 51, 689-700.
50. Kovacs SJ, Martin DE, Everitt DE, Patterson SD, Jorkasky DK (1998) Urinary excretion of 6 beta-hydroxycortisol as an in vivo marker for CYP3A induction: applications and recommendations. Clinical Pharmacology and Therapeutics, 63, 617-622.
51. Hunt CM, Watkins PB, Saenger P et al. (1992) Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol. Clinical Pharmacology and Therapeutics, 51, 18-23.
52. Kinirons MT, O'Shea D, Downing TE et al. (1993) Absence of correlations among three putative in vivo probes of human cytochrome P4503A activity in young healthy men. Clinical Pharmacology and Therapeutics, 54, 621-629.
53. Gill HJ, Tingle MD, Park BK (1995) N-Hydroxylation of dapsone by multiple enzymes of cytochrome P450: implications for inhibition of haemotoxicity. British Journal of Clinical Pharmacology, 40, 531-538.
54. Schmider J, Greenblatt DJ, Fogelman SM, von Moltke LL, Shader RI (1997) Metabolism of dextromethorphan in vitro: involvement of cytochromes P450 2D6 and 3A3/4, with a possible role of 2E1. Biopharmaceutics & Drug Disposition, 18, 227-240.
55. Tanaka E (1999) Update: genetic polymorphism of drug metabolizing enzymes in humans. Journal of Clinical Pharmacology and Therapeutics, 24, 323-329.
56. Fuhr U, Rost KL (1994) Simple and reliable CYP1A2 phenotyping by the paraxanthine/caffeine ratio in plasma and in saliva. Pharmacogenetics, 4, 109-116.
57. Spigset O, Hagg S, Soderstrom E, Dahlqvist R (1999) The paraxanthine: caffeine ratio in serum or in saliva as a measure of CYP1A2 activity: when should the sample be obtained? Pharmacogenetics, 9, 409-412.
58. Tantcheva-Poor I, Zaigler M, Rietbrock S, Fuhr U (1999) Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test. Pharmacogenetics, 9, 131-144.
59. Hou ZY, Pickle LW, Meyer PS, Woosley RL (1991) Salivary analysis for determination of dextromethorphan metabolic phenotype. Clinical Pharmacology and Therapeutics, 49, 410-419.
60. Dierks EA, Stams KR, Lim HK, Cornelius G, Zhang H, Ball SE (2001) A method for the simultaneous evaluation of the activities of seven major human drug-metabolizing cytochrome P450s using an in vitro cocktail of probe substrates and fast gradient liquid chromatography tandem mass spectrometry. Drug Metabolism and Disposition, 29, 23-29.